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A B S T R A C T
Atrial ﬁbrillation (AF), the most common persistent clinical tachyarrhythmia, is associated with altered gene
transcription which underlies cardiomyocyte dysfunction, AF susceptibility and progression. Recent research
showed class I and class IIa histone deacetylases (HDACs) to regulate pathological and fetal gene expression, and
thereby induce hypertrophy and cardiac contractile dysfunction. Whether class I and class IIa HDACs are in-
volved in AF promotion is unknown. We aim to elucidate the role of class I and class IIa HDACs in tachypacing-
induced contractile dysfunction in experimental model systems for AF and clinical AF.
Methods and results: Class I and IIa HDACs were overexpressed in HL-1 cardiomyocytes followed by calcium
transient (CaT) measurements. Overexpression of class I HDACs, HDAC1 or HDAC3, signiﬁcantly reduced CaT
amplitude in control normal-paced (1 Hz) cardiomyocytes, which was further reduced by tachypacing (5 Hz) in
HDAC3 overexpressing cardiomyocytes. HDAC3 inhibition by shRNA or by the speciﬁc inhibitor, RGFP966,
prevented contractile dysfunction in both tachypaced HL-1 cardiomyocytes and Drosophila prepupae.
Conversely, overexpression of class IIa HDACs (HDAC4, HDAC5, HDAC7 or HDAC9) did not aﬀect CaT in
controls, with HDAC5 and HDAC7 overexpression even protecting against tachypacing-induced CaT loss.
Notably, the protective eﬀect of HDAC5 and HDAC7 was abolished in cardiomyocytes overexpressing a domi-
nant negative HDAC5 or HDAC7 mutant, bearing a mutation in the binding domain for myosin enhancer factor 2
(MEF2). Furthermore, tachypacing induced phosphorylation of HDAC5 and promoted its translocation from the
nucleus to cytoplasm, leading to up-regulation of MEF2-related fetal gene expression (β-MHC, BNP). In accord,
boosting nuclear localization of HDAC5 by MC1568 or Go6983 attenuated CaT loss in tachypaced HL-1 cardi-
omyocytes and preserved contractile function in Drosophila prepupae. Findings were expanded to clinical AF.
Here, patients with AF showed a signiﬁcant increase in expression levels and activity of HDAC3, phosphorylated
HDAC5 and fetal genes (β-MHC, BNP) in atrial tissue compared to controls in sinus rhythm.
Conclusion: Class I and class IIa HDACs display converse roles in AF progression. Whereas overexpression of
Class I HDAC3 induces cardiomyocyte dysfunction, class IIa HDAC5 overexpression reveals protective proper-
ties. Accordingly, HDAC3 inhibitors and HDAC5 nuclear boosters show protection from tachypacing-induced
changes and therefore may represent interesting therapeutic options in clinical AF.
1. Introduction
Atrial ﬁbrillation (AF) is the most common sustained and pro-
gressive clinical tachycardia which contributes to cardiovascular mor-
bidity and mortality [1]. AF is characterized by speciﬁc electrical,
transcriptional and structural changes in the cardiomyocyte, commonly
denoted as remodeling [2]. Cardiomyocyte remodeling underlies con-
tractile dysfunction and the progression of AF. Therefore, it is of great
interest to dissect the molecular mechanisms underlying cardiomyocyte
remodeling, with the aim to identify novel druggable targets which
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attenuate remodeling and AF progression.
Previous research identiﬁed that (re)activation of pathological and
fetal gene program in cardiomyocytes promotes AF onset and pro-
gression [3,4]. Ausma et al. showed upregulation of two proteins of the
fetal program in the goat model for AF, i.e. the slow-contracting beta-
myosin heavy chain isoform (β-MHC) and smooth muscle α-actin (α-
SMA) [5–8]. In persistent AF patients, numerous fetal/neonatal variants
of the titin protein were observed in cardiac myoﬁbrils, and atrial re-
expression of TnI-skeletal-slow-twitch (ssTnI) was found in patients
with paroxysmal AF [9]. In addition, persistent AF was associated with
higher cardiac mRNA expression of brain natriuretic peptide (BNP)
[10]. Interestingly, pathological and fetal gene expression is under
control of epigenetic regulation [11–15]. Hence, epigenetic regulation
has been identiﬁed as an important mechanism underlying the pro-
gression of cardiac diseases [11–15]. Epigenetic regulation refers to
processes that inﬂuence the packaging or processing of nuclear DNA,
thus controlling the on/oﬀ states of multiple genes with discrete
switches. The packaging of chromatin is largely dependent on the
acetylation status of histones, which is controlled by histone acetyl
transferases and histone deacetylases (HDACs) [11–15]. HDACs are an
ancient family of enzymes that catalyze the removal of acetyl groups
from the ε-amino group of speciﬁc acetyl lysine residues within their
protein substrates. In general, deacetylation of histones in nucleosomes
induces chromatin condensation, which inhibits binding of transcrip-
tion factors and other components of the transcriptional machinery to
gene promoter and enhancer regions, ultimately resulting in tran-
scriptional repression. As such, histone deacetylation serves as an im-
portant regulator of gene expression.
The zinc-dependent HDACs are classiﬁed into four groups based on
their structure, complex formation, and expression pattern: class I
(HDAC1, HDAC2, HDAC3, and HDAC8), class IIa (HDAC4, HDAC5,
HDAC7, and HDAC9), class IIb (HDAC6 and HDAC10), and class IV
(HDAC11) [16]. We recently reported on a cytosolic member of HDAC
class IIb, HDAC6, and its prominent role in AF progression [17]. HDAC6
deacetylates α-tubulin, which causes disruption of microtubule struc-
ture, contractile dysfunction and AF progression [17]. However, whe-
ther the other HDAC classes are involved in AF progression is unknown.
Of the four classes, class I and IIa are well studied regarding their role in
pathological gene expression, structural changes and the development
of hypertrophy and heart failure [18–21]. Class I HDACs reveal high
HDAC activity in cardiomyocytes, but ﬁndings on their role in cardiac
disease development are conﬂicting [18]. In recent years, class IIa
HDACs, especially HDAC4, HDAC5 and HDAC9, have attracted con-
siderable attention as regulators of transcriptional reprogramming
especially in cardiac diseases. Under normal circumstances, class IIa
HDACs localize in the nucleus and suppress cardiomyocyte hypertrophy
by repressing the activity of pro-hypertrophic transcription factors,
such as members of the myocyte enhancer factor-2 (MEF2) family
[19,20]. In response to stress signals, class IIa HDACs are phosphory-
lated and exported from the nucleus, thereby activating transcriptional
reprogramming and the induction of hypertrophic gene expression re-
sulting in cardiac disease [18–21].
Although previously ﬁndings indicate a role for transcriptional re-
modeling in AF progression [3], and our previous study revealed a
prominent role for the cytosolic member of HDAC class IIb, HDAC6, in
AF progression [17], the involvement of class I and class IIa HDACs in
AF is still unknown. Therefore, we examined the role of class I and IIa
HDACs on contractile function in tachypaced HL-1 cardiomyocytes and
Drosophila, followed by exploration of the downstream pathway. Ex-
perimental ﬁndings were conﬁrmed in AF patients. Here, we show that
HDAC3 overexpression causes contractile dysfunction in HL-1 cardio-
myocytes. Both pharmacological and genetic inhibition of HDAC3
prevents tachypacing-induced contractile dysfunction in experimental
models for AF progression. In contrast, class IIa HDAC5 and HDAC7
overexpression protects against tachypacing-induced contractile dys-
function, possibly via prevention of MEF2 related fetal gene expression,
including β-MHC and BNP expression [19,20]. In line, HDAC5 nuclear
boosters attenuated tachypacing-induced contractile dysfunction in
experimental models for AF. Finally, ﬁndings for HDAC3 and HDAC5
were conﬁrmed in atrial tissue biopsies from patients with AF compared
to control patients in sinus rhythm (SR), indicating activation of HDAC
class I and IIa in patients with AF.
2. Materials and methods
2.1. Tachypacing of HL-1 cardiomyocytes and calcium transient
measurements
HL-1 cardiomyocytes were subjected to tachypacing (TP, 5 Hz, 40 V,
pulse duration of 20ms) with a 4-well C-pace system from IonOptix for
12 h except speciﬁcally stated for time-course pacing, followed by cal-
cium transient measurements as described before [17]. See Supple-
mental Information section of detailed information.
2.2. Plasmids
Retroviral constructs of HDACs and HDACs mutants (HDACm) were
generated in the lab of Dr. Miguel A. Esteban [22]. To facilitate the
detection of HDAC overexpression by Western blot analyses, the con-
structs contained a FLAG tag in the carboxyl terminal. DNA mutagen-
esis of HDAC5 and HDAC7 in the MEF2 binding domain was produced
using suitable oligos and a PCR-based method. All new plasmids were
veriﬁed by sequencing before use [22]. GFP-HDAC5 constructs were a
generous gift from Dr. Johannes Backs' lab [18].
2.3. Retroviral infection of HL-1 cardiomyocytes
Generation of retro-virus and infection of HL-1 cardiomyocytes
were performed as previously described [22]. See Supplemental In-
formation section of detailed information.
2.4. Drosophila stocks, tachypacing, and heart wall contraction assays
The Drosophila wild-type W1118 strain was used for all drug
screening experiments. Information on Drosophila stocks [23], crossing,
tachypacing (TP, 4 Hz, 20 V, pulse duration of 5ms) and heart wall
contraction assays are described in the Supplemental Information sec-
tion.
2.5. Real time PCR
Total RNA from HL-1 cardiomyocytes, Drosophila and human tissue
was isolated by use of TRIzol reagent (Invitrogen) and 0.5 μg RNA per
sample was used for synthesizing cDNA by utilizing the Reverse
Transcriptional kit (Invitrogen) following the manufacturer's instruc-
tions. Gene expression was determined by quantitative real time PCR on
a Bio-Rad CFX384 real time system using SYBR green dye (Invitrogen).
Gene expression was corrected for levels of the reference gene GAPDH.
Primer sequences are listed in Supplemental Information section Table
S1.
2.6. Protein extraction and Western blot analysis
HL-1 cardiomyocytes or human tissue samples were used for protein
extraction and Western blot analyses as described in the Supplemental
Information section.
2.7. Immunoﬂuorescence
Detailed information on immunoﬂuoresent staining procedures can
be found in Supplemental Information section.
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2.8. Patients
Before surgery, one investigator assessed patient characteristics
(Table 1), as described before [24]. Right atria appendages (RAA) and
left atria appendages (LAA) were obtained from patients with (long
standing) persistent AF (PeAF) and control patients in SR. After exci-
sion, atrial appendages were immediately snap-frozen in liquid nitrogen
and stored at −80 °C. The study conforms to the principles of the De-
claration of Helsinki. The Institutional Review Board approved the
study, and patients gave written informed consent. Tissues were used to
perform real time PCR and Western blot experiments.
2.9. Statistical analysis
Results are expressed as mean ± SEM. Biochemical analyses were
performed at least in duplicate. Individual group mean diﬀerences were
evaluated with the Students t-test. Categorical data diﬀerences were
evaluated with Pearson's chi-squared test. All P values were 2-sided.
Values of P < 0.05 were considered statistically signiﬁcant. SPSS
version 22 was used for all statistical evaluations.
3. Results
3.1. Screening role of class I and IIa HDACs on tachypacing-induced
remodeling in HL-1 cardiomyocytes
To study the role of class I and IIa HDACs on contractile function in
cardiomyocytes, various members of the HDAC classes were over-
expressed in HL-1 cardiomyocytes by retroviral infection (Supplemental
Fig. S1A, B). Control DsRED retroviral infected HL-1 cardiomyocytes
revealed normal CaT amplitudes, which were signiﬁcantly reduced
after tachypacing (Fig. 1A, B, Supplemental Fig. S2). Of the examined
class I HDACs, HDAC1 or HDAC3 overexpression resulted in CaT loss in
normal paced cardiomyocytes which was further reduced by tachypa-
cing in HDAC3 but not in HDAC1 overexpressing cardiomyocytes
(Fig. 1B). This result indicates a detrimental eﬀect of overexpression of
class I HDACs, especially HDAC3, on contractile function in HL-1 car-
diomyocytes.
Overexpression of class IIa HDACs, i.e. HDAC4, HDAC5, HDAC7 and
HDAC9, rendered mixed results. None of the class IIa HDACs caused
CaT changes in control HL-1 cardiomyocytes (Fig. 1A, C). Over-
expression of HDAC5 and HDAC7 signiﬁcantly precluded tachypacing-
induced decline in CaT in HL-1 cardiomyocytes, whereas over-
expression of HDAC4 or HDAC9 were not protective (Fig. 1A, C). Under
normal circumstances, HDAC5 and HDAC7 are localized in the nucleus
and bind to MEF2, via their MEF2 binding domain, resulting in re-
pression MEF2 activity [19,20]. In response to stress signals, HDAC5
and HDAC7 are phosphorylated and exported from the nucleus, thereby
activating MEF2 and permitting the induction of pathological fetal gene
expression [19,20]. To test whether the protective eﬀect of HDAC5 and
HDAC7 is via binding to MEF2, HL-1 cardiomyocytes were transfected
with mutant HDAC5m or HDAC7m with a dysfunction MEF2 binding
domain. Notably, loss of MEF2 binding capacity abrogated their pro-
tection from tachypacing-induced CaT loss (Fig. 1C), suggesting that
binding of HDAC5 and HDAC7 to MEF2 prevents cardiomyocyte re-
modeling.
Consequently, our ﬁndings suggest converse roles of class I and class
IIa HDACs in tachypacing-induced remodeling in HL-1 cardiomyocytes.
Overexpression of class I HDACs, especially HDAC3, causes contractile
dysfunction, while overexpression of IIa HDAC5 and HDAC7 protects
against tachypacing-induced CaT loss, possibly via nuclear binding to
MEF2 transcription factor and thus limiting downstream pathological
reprogramming.
3.2. Knockdown of HDAC3 protects against tachypacing-induced
contractile dysfunction in experiment models for AF
To study the role of class I HDAC3 in contractile dysfunction in
more detail and test whether HDAC3 may represent a druggable target
in AF, HDAC3 expression and activity levels were measured in tachy-
paced HL-1 cardiomyocytes and in RAA and LAA of patients with PeAF
and control patients in SR. In HL-1 cardiomyocytes, tachypacing sig-
niﬁcantly increased HDAC3 protein levels as conﬁrmed by immuno-
ﬂuorescent staining (Fig. 2A, B), and HDAC3 activity levels as indicated
by increased deacetylation of its target acetyl histone 4 at lysine 5
(AcH4k5) [25] (Fig. 2C, D). In line with tachypaced HL-1 cardiomyo-
cytes, PeAF patients revealed signiﬁcant higher levels of HDAC3 ex-
pression and activity, as indicated by increased deacetylation of its
target AcH4k5, in left and right atrial appendages compared to control
patients in SR (Fig. 3A-C).
To examine whether HDAC3 knockdown improves contractile
function in HL-cardiomyocytes, HDAC3 was suppressed by retro-viral
infection of HDAC3 shRNA in HL-1 cardiomyocytes (Fig. 4A). As ex-
pected, HDAC3 knockdown signiﬁcantly protected against tachypacing-
induced CaT loss in HL-1 cardiomyocytes, while HDAC1 knockdown
did not reveal an eﬀect (Fig. 4B, C). Consistently, HDAC3 knockdown in
the Drosophila heart also protected against tachypacing-induced con-
tractile dysfunction, including heart rate reduction and increased ar-
rhythmicity (Fig. 4E-G). Taken together, these data suggest that HDAC3
contributes to AF remodeling and progression and thus inhibition of
HDAC3 may represent a druggable target in AF.
3.3. Tachypacing induces HDAC5 phosphorylation and its nuclear export in
HL-1 cardiomyocytes
Conversely to HDAC3, class IIa HDAC5 and HDAC7 protected
against tachypacing-induced CaT loss in HL-1 cardiomyocytes. Of these
two protective class IIa HDACs, HDAC5 represents an interesting can-
didate, because its expression is abundant in the heart in contrast to
HDAC7 [20,26,27], and its function is regulated by calpain [28], which
was previously found to induce structural remodeling in AF via de-
gradation of HDAC6-deacetylated microtubules [17]. Therefore, we
determined the role of HDAC5 in cardiomyocytes in more detail. Upon
stress, HDAC5 gets phosphorylated, resulting in dissociation of HDAC5
from MEF2, and its nuclear export [26,28–30]. Firstly, we studied
whether tachypacing induces HDAC5 phosphorylation in HL-1
Table 1
Baseline demographic and clinical characteristics of patients with PeAF and
control patients in SR.
SR PeAF
N 12 12
RAA (n) 12 12
LAA (n) 7 7
Age (mean, std) 60 ± 17 69 ± 5
Months of AF (median, range) – 22 (4–244)
Persistent AF _ 5
Long-standing persistent AF _ 7
Underlying heart disease (n)/surgical procedure
MVD/MV replacement or repair 8 (67%) 11 (92%)
CABG 4 (33%) 1 (8%)
AVD 1 (8%) 1 (8%)
Medication (n)
ACE / ARB 7 (58%) 10 (83%)
Digoxin 0 (0%) 4 (33%)
Ca2+ channel blocker 0 (0%) 2 (17%)
β-blocker 5 (42%) 8 (67%)
Statin 7 (58%) 3 (25%)
Maze: atrial arrhythmia surgery; MVD: mitral valve disease; AVD: aortic valve
disease; ACE: angiotensin-converting enzyme; CABG: coronary artery bypass
surgery; ARB: angiotensin receptor blockers; β-Blocker: beta-adrenergic an-
tagonists.
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cardiomyocytes. As expected, tachypacing gradually and signiﬁcantly
increased phosphorylation of HDAC5 in HL-1 cardiomyocytes (Fig. 5A,
B). Secondly, we determined the localization of HDAC5 in the HL-1
cardiomyocytes both by transfection of GFP-HDAC5 and
immunostaining of endogenous HDAC5. In control cardiomyocytes (0 h
TP), over 50% of GFP-HDAC5 was found exclusively in the nucleus
(Fig. 5C, D). During tachypacing, the percentage of nuclear GFP-HDAC5
decreased gradually, and after 12 h tachypacing,< 10% of the
Fig. 1. Converse role of Class I and IIa HDACs in
regulation of contractile function in HL-1 cardi-
omyocytes. A) Representative CaT traces of HL-1
cardiomyocytes, showing that cardiomyocytes
overexpressing HDAC5 or HDAC7 are protected
against tachypacing-induced CaT reduction. B,C)
Quantiﬁed data showing relative CaT amplitudes
of non-paced (NP) and tachypaced (TP) cardio-
myocytes, each from groups as indicated.
Cardiomyocytes were infected with control
plasmid DsRED retrovirus (CTL), HDAC1,
HDAC3, HDAC4, HDAC5, HDAC7,HDAC9,
HDAC5 mutant (HDAC5m) or HDAC7 mutant
(HDAC7m) retrovirus. HDAC5m, HDAC7m have
mutations in MEF2 binding domains and there-
fore cannot ﬁnd to MEF2. *P < 0.05 vs CTL NP,
***P < 0.001 vs CTL NP, #P < 0.01 HDAC TP
vs CTL TP. N≥ 8 for each group.
Fig. 2. Tachypacing increases HDAC3 protein and activity levels in HL-1 cardiomyocytes. A, B) Representative immunoﬂuoresent staining and quantiﬁed data of
HDAC3 in non-paced (NP) and tachypaced (TP) HL-1 cardiomyocytes. N= 24 images for NP, N=49 images for TP, from over 1000 cardiomyoyctes. ***P < 0.001
vs NP. C, D) Representative Western blot and quantiﬁed data of acetyl-Histone H4 lysine 5 (AcH4K5), an HDAC3 substrate, indicating increased HDAC3 activity after
TP. N=4 experiments per group. *P < 0.05 vs NP.
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cardiomyocytes revealed exclusively nuclear staining of HDAC5
(Fig. 5C, D). Similar ﬁndings were observed for endogenous HDAC5,
which was localized in the nucleus in control conditions and exported
to the cytoplasm following tachypacing (Supplemental Fig. 3A, B).
Together, these results demonstrate tachypacing to induce phosphor-
ylation and nuclear export of HDAC5 in HL-1 cardiomyocytes.
3.4. MEF2 regulates fetal gene expression in tachypaced HL-1
cardiomyocytes
Upon tachypacing, nuclear HDAC5 is phosphorylated, released from
MEF2 and exported to the cytosol [26,28–30], which allows the histone
acetyltransferase p300 to associate with MEF2 via the HDAC docking
site, thereby converting MEF2 from a transcriptional repressor to a
transcriptional activator of fetal genes, including β-MHC and BNP
[19,20]. To test whether tachypacing induces the expression of β-MHC,
HL-1 cardiomyocytes were tachypaced and mRNA levels of β-MHC and
α-MHC levels were determined by quantitative PCR with reverse
transcription (RT–PCR). The ratio of β-MHC to α-MHC increased sig-
niﬁcantly after 12 h tachypacing in HL-1 cardiomyocytes (Fig. 6A).
Interestingly, tachypacing induced a gradual and signiﬁcant induction
of BNP mRNA in HL-1 cardiomyocytes (Fig. 6B), as was previously
found in persistent AF [10]. In addition, tachypacing-induced BNP le-
vels, correlate signiﬁcantly with the phosphorylated HDAC5 levels
(Fig. 6C). These results reveal that tachypacing induces the expression
of fetal genes in HL-1 cardiomyocytes, which correlates partly with
HDAC5 phosphorylation.
3.5. HDAC5 phosphorylation and fetal gene expression are induced in
persistent AF patients
To investigate whether a similar modulating role of HDAC5 is found
in patients with AF, the amount of phosphorylated HDAC5 was mea-
sured in LAA and RAA of patients with PeAF and controls in normal SR.
A signiﬁcant increase in the level of phosphorylated HDAC5 was ob-
served in the LAA of patients with PeAF compared to SR controls
(Fig. 7A, B). Moreover, the gene expression levels of β-MHC, α-MHC
and BNP were determined. Comparable to tachypaced HL-1 cardio-
myocytes, a signiﬁcant induction in the ratio of β-MHC/α-MHC in the
RAA and increased expression of BNP in the LAA was observed in pa-
tients with PeAF compared to control SR patients (Fig. 7C, D). Again the
induction of BNP correlated signiﬁcantly with phosphorylated HDAC5
levels (Fig. 7E), consistent with the results in tachypaced HL-1
cardiomyocyte (Fig. 6C). Our ﬁndings in patients with PeAF indicate
that phosphorylation of HDAC5 and subsequent activation of MEF2-
related fetal gene expression underlies cardiomyocyte remodeling and
AF progression, especially in the LAA.
3.6. HDAC3 inhibitor and HDAC5 nuclear boosters protect against
tachypacing-induced contractile dysfunction in HL-1 cardiomyocytes and in
Drosophila
Given that HDAC3 knockdown protects against contractile dys-
function in both cardiomyocyte and Drosophila models for AF, we ex-
pect the speciﬁc HDAC3 inhibitor, RGFP966, to protect against tachy-
pacing-induced contractile dysfunction in experimental models for AF.
As expected, RGFP966 pretreatment signiﬁcantly prevented tachypa-
cing-induced CaT loss in HL-1 cardiomyocytes (Fig. 8A, B and Supple-
mental Fig. S4A). RGFP966 also signiﬁcantly protected against tachy-
pacing-induced heart rate reduction and increased arrhythmicity index
in the Drosophila model for AF (Fig. 8C-E).
Our results also suggest that HDAC5 protects against AF-remodeling
and may represent an interesting therapeutic target to prevent patho-
logical fetal gene expression, functional loss and AF progression.
Consequently, compounds boosting HDAC5 nuclear localization and
thereby inhibiting the release of HDAC5 from MEF2, may have a
therapeutic potential for treatment of AF and it is of interest to test
these compounds in experimental AF. One such compound is MC1568,
since it inhibits the activity of HDAC4 and HDAC5, thereby leaving
MEF2-HDAC complexes in a repressed state [31]. The other compound
is the PKC inhibitor Go6983, which has been reported to block HDAC5
nuclear export [28,32]. We tested MC1568 and Go6983 in tachypaced
HL-1 cardiomyocytes and Drosophila prepupae. Both compounds in-
creased the nuclear HDAC5 level and protected against the CaT loss in
tachypaced HL-1 cardiomyocytes (Fig. 9A, B; Supplemental Figs. S4B-F
and S5A, B). They also protected against the reduction in heart rate and
increased arrhythmicity in tachypaced Drosophila prepupae (Fig. 9C-E,
Supplemental Fig. S5C-E).
The ﬁndings indicate that both HDAC3 inhibitors and HDAC5 nu-
clear boosters may represent promising novel compounds to prevent AF
promotion.
4. Discussion
In the current study, we evaluated the role of class I and class IIa
HDACs in tachypacing-induced cardiomyocyte remodeling. We found
Fig. 3. HDAC3 protein and activity levels are in-
creased in PeAF patients compared to SR. A, B)
Representative Western blot and quantiﬁed data of
HDAC3 in patients with SR and PeAF. *P < 0.05 SR
RAA vs AF RAA, **P < 0.01 SR LAA vs PeAF LAA.
N=7 for SR RAA, N=8 for PeAF RAA, N=5 for
SR LAA and N=5 for PeAF LAA. C) Quantiﬁed data
of AcH4K5 levels for the groups as indicated, re-
vealing signiﬁcant increased HDAC3 activity in PeAF
patients. *P < 0.05 SR RAA vs PeAF RAA. N=9 for
SR RAA, N=9 for PeAF RAA, N=4 for SR LAA and
N=4 for PeAF LAA.
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that overexpression of class I members, HDAC1 and HDAC3, results in
detrimental eﬀects on contractile function in HL-1 cardiomyocytes.
Also, HDAC3 expression and activity levels were increased in atrial
tissue from PeAF patients compared to controls in SR, indicating a role
for HDAC3 in clinical AF. In line, genetic and pharmacological inhibi-
tion of HDAC3 protected against tachypacing-induced contractile dys-
function in both HL-1 cardiomyocytes and Drosophila, suggesting that
HDAC3 inhibition protects against AF remodeling.
In contrast, overexpression of class IIa HDAC5 and HDAC7 revealed
protective eﬀects against tachypacing-induced contractile dysfunction
via binding to MEF2, thereby possibly preventing fetal gene expression.
In addition, tachypacing resulted in phosphorylation of HDAC5, nuclear
export and downstream fetal gene activation in HL-1 cardiomyocytes.
The experimental ﬁndings were conﬁrmed in atrial appendages of pa-
tients with PeAF. In line, compounds which boost nuclear HDAC5 at-
tenuated tachypacing-induced contractile dysfunction in both HL-1
cardiomyocytes and Drosophila.
Taken together, the ﬁndings suggest that HDAC3 and HDAC5 are
interesting therapeutic targets in AF.
Fig. 4. HDAC3 knockdown protects against tachypacing-induced contractile dysfunction in both HL-1 cardiomyocytes and Drosophila. A) Western blot showing
successful knockdown of HDAC3 with retro viral HDAC3 shRNA compared to Luciferase shRNA (CTL) in HL-1 cardiomyocytes. B,C) Representative CaT traces and
quantiﬁed data showing that knockdown of HDAC3 protects against tachypacing-induced CaT loss in HL-1 cardiomyocytes. **P < 0.01, ***P < 0.001 vs CTL NP,
###P < 0.001 vs CTL TP. N=10 cardiomyocytes per group. D) Representative qPCR showing signiﬁcant knockdown of HDAC3 in Drosophila. *P < 0.05 HDAC3
knockdown (HDAC3KD) vs wild type control (WT). N=2 experiments for WT, N=3 for HDAC3KD. E) Representative heart wall traces (10 s) prepared from high-
speed movies of Drosophila prepupa. Movies were made in non-tachypaced (NP) and after tachypacing (TP) of Drosophila prepupa. Heart period (HP) is the time
interval between two beats. Heart rate (BPM: beats per minute) is calculated by mean of HP divided by 1min. Arrhythmicity index is calculated as the standard
deviation of HP in milliseconds (ms). F, G) Quantiﬁed heart rate and arrhythmicity index of NP and TP in WT and HDAC3KDDrosophila, showing HDAC3 knockdown
signiﬁcantly protected against tachypacing-induced heart rate loss and increased arrhythmicity index. ***P < 0.001 vs WT NP, #P < 0.5 vs WT TP. N≥ 11
Drosophila per group.
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Fig. 5. Tachypacing incudes HDAC5 phosphorylation and nuclear export. A) Representative Western blot of phosphorylated HDAC5 (pHDAC5), HDAC5 and GAPDH
in HL-1 cardiomyocytes tachypaced for the duration as indicated. B) Quantiﬁed ratio of pHDAC5 to HDAC5 from at least 3 independent experiments. *P < 0.05 vs
0 h, ***P < 0.001 vs 0 h. C) Representative confocal images of cardiomyocytes transfected with HDAC5-GFP construct showing the localization of HDAC5 in HL-1
cardiomyocytes tachypaced from 0 h to 12 h. D) Quantiﬁed data of cellular localization of HDAC5, showing signiﬁcant decrease in nuclear localization and signiﬁcant
increase in cytosolic localization of HDAC5 after 12 h TP. ***P < 0.001 vs 0 h chi-square test. N≥ 22 cardiomyocytes per group.
Fig. 6. Activation of fetal gene program in tachy-
paced HL-1 cardiomyocytes. A) Time course of TP-
induced increase in gene expression ratio of β-MHC
(MHY7) to α-MHC (MHY6). *P < 0.05,
***P < 0.001 vs 0 h. B) BNP gene expression is
signiﬁcantly increased during TP. ***P < 0.01 vs
0 h. C) BNP gene expression level correlates sig-
niﬁcantly with level of pHDAC5 during time-course
of TP.
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4.1. Role of class I HDACs in cardiac growth and disease
In the present study, overexpression of members of the class I HDAC
family, HDAC1 and HDAC3 show detrimental eﬀects on normal con-
tractile function of HL-1 cardiomyocytes. Class I HDACs control ex-
pression of a vast array of genes involved in core cellular activities, such
as cell proliferation and death [33]. All class I HDAC members are
ubiquitously expressed in the heart, localize predominantly in the nu-
cleus and display high enzymatic activity toward histone substrates
[33]. Redundant functions of HDAC1 and HDAC2 have been described
by Olson's lab, i.e. cardiac deletion of either HDAC1 or HDAC2 does not
substantially interfere with normal heart development, whereas cardiac
deletion of both HDAC1 and HDAC2 results in neonatal lethality, ac-
companied by cardiac arrhythmias, dilated cardiomyopathy, and up-
regulation of genes encoding skeletal muscle-speciﬁc contractile pro-
teins and calcium channels in the heart [34]. Trivedi et al. found that in
HDAC2-deﬁcient mice exposed to hypertrophic stimuli, cardiac hyper-
trophy and ﬁbrosis were attenuated and that cardiac-speciﬁc over-
expression of HDAC2 resulted in cardiac hypertrophy [35]. The recent
ﬁnding that HDAC1 and HDAC2 play a major role in autophagy driven
by α-adrenergic stimulation in cultured cardiomyocytes provides an-
other indication that HDAC1 and HDAC2 may act as a driver of adverse
cardiac remodeling [36]. Although the roles of the class I HDACs,
HDAC1 and HDAC2, in cardiac hyperplasia, growth, and hypertrophic
responsiveness have been reported, the role of HDAC3 in the heart has
been less well explored. Cardiomyocyte-speciﬁc overexpression of
HDAC3 in mice results in cardiac abnormalities at birth and increased
cardiac wall thickness due to increased cardiomyocyte hyperplasia
[37]. Consistent with its detrimental role in heart development and
contraction, we observed HDAC3 to play a role in AF promotion.
HDAC3 expression and activity are increased in atrial tissue of AF pa-
tients and in tachypaced HL-1 cardiomyocytes, suggesting HDAC3 to
contribute to AF progression, possibly via changing the expression of
ion-channels and contractile proteins, as have been observed for
HDAC1 and HDAC3 [34]. In line, HDAC3 knockdown or HDAC3 in-
hibition prevented against contractile dysfunction in tachypaced HL-1
and Drosophila models for AF, suggesting HDAC3 as a potential drug-
gable target in AF.
4.2. Key role for class IIa HDAC5 in AF
In the present study, we identiﬁed a key role for tachypacing-in-
duced activation, nuclear export of HDAC5, and consequently tran-
scriptional reprogramming in cardiomyocytes. In general, class IIa
HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) all have large N-term-
inal extensions with conserved binding sites for the transcription factor
MEF2 and the chaperone protein 14-3-3 (Supplemental Fig. S6A).
Binding of MEF2 to these sites results in suppression of transcriptional
activity [19,38]. Following phosphorylation by kinases, such as cal-
cium/calmodulin-dependent protein kinase (CaMK), which is activated
in AF [39], class IIa HDACs bind 14–3-3 and shuttle from the nucleus to
the cytoplasm [19,38,40]. The dissociation of class IIa HDACs from
MEF2 allows the histone acetyltransferase p300 to associate with MEF2
via the HDAC docking site, thereby converting MEF2 from a tran-
scriptional repressor (MEF2-HDAC complex) to a transcriptional acti-
vator (MEF2-p300 complex) of fetal gene program [19,38,40]. In re-
sponse to injury, MEF2 is activated resulting in pathological cardiac
hypertrophy and heart failure [41].
Fig. 7. pHDAC5 levels correlate with BNP gene ex-
pression levels in LAA of AF patients. A)
Representative Western blot of phosphorylated
HDAC5 (pHDAC5), HDAC5 and GAPDH in patients
with PeAF. B) Quantiﬁed ratio of pHDAC5 to HDAC5
in patients. N=5 from each group. ***P < 0.001
PeAF vs SR. C) The gene expression ratio of β-MHC
(MHY7) to α-MHC (MHY6) is signiﬁcantly increased
in PeAF patients. *P < 0.05 vs SR RAA. N=6 for
SR, N=7 for PeAF. D) BNP gene expression is sig-
niﬁcantly increased in PeAF patients. ***P < 0.001
vs SR LAA. N=6 for SR, N=7 for PeAF. E) BNP
gene expression level correlates signiﬁcantly with
pHDAC5 levels in patients (SR N=3 for LAA/RAA,
PeAF N=5 for LAA/RAA). Open circles: SR, ﬁlled
circles: PeAF.
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Although all members of Class IIa HDACs can bind to MEF2 to
suppress fetal gene expression, hypertrophy and heart failure, in the
current study we observed a protective role for HDAC5 and HDAC7, but
not HDAC4 and HDAC9, in tachypacing-induced remodeling
(Supplemental Fig. S6B). This discrepancy may be explained by ta-
chypacing-induced activation of particular upstream kinases which
only induce phosphorylation of speciﬁc members of HDAC class IIa.
Furthermore, speciﬁc HDAC class IIa members may aﬀect diﬀerent
downstream targets that aﬀect cardiac remodeling. An example of the
latter is the recently described non-transcriptional function for HDAC4
in the heart comprising its association with cardiac sarcomeres and
lowering of myoﬁlament calcium sensitivity [42]. In our study, a pos-
sible protective role of HDAC4 to suppress MEF2 related fetal gene
expression may have been oﬀset by the HDAC4 detrimental eﬀect on
contractile function. Moreover, HDAC4 binds constitutively to 14-3-3 in
yeast and mammalian cells, whereas HDAC5 binding to 14-3-3 is de-
pendent on CaMK signaling. In addition, 14-3-3 binding to HDAC5 is
required for CaMK-dependent disruption of MEF2-HDAC complexes
and nuclear export of HDAC5 [43,44]. Since CaMK signaling is involved
in AF progression, the role of speciﬁc upstream kinases seems plausible.
The involvement of HDAC7 in heart diseases has not been studied well.
However, there are indications for HDAC7 to regulate the function of
MEF2 proteins in heart and muscle tissue [45], suggesting a similar role
as HDAC5.
HDAC5 and HDAC9 have redundant roles in the suppression of
cardiac growth in response to stress signaling, and both are highly
enriched in the heart compared to HDAC7 [26,27]. Despite sharing
common upstream kinases, which stimulate the translocation of HDAC5
and HDAC9, only translocation of HDAC5 is activated by calpain
[26–28]. Interestingly, calpain was found to be activated in AF and
underlies structural remodeling and contractile dysfunction in AF [24].
Thus, calpain-induced HDAC5 activation may be involved in tran-
scriptional reprogramming and cardiomyocyte remodeling as observed
in AF.
4.3. Therapeutic implications
In the current study, we observed opposite key roles for class I
HDAC3 and class IIa HDAC5 in AF remodeling. Class I HDAC3 over-
expression caused contractile dysfunction in HL-1 cardiomyocyte model
for AF. Also, HDAC3 protein and activity are both increased in tachy-
paced HL-1 cardiomyocytes and in AF patients. Both pharmacological
and genetic inhibition of HDAC3 prevented contractile dysfunction in
HL-1 and Drosophila model for AF. Speciﬁc HDAC3 inhibitor, RGFP966,
thus represents an interesting compound to be tested in big animal
model for AF and ultimately in clinical AF. On the contrary, class IIa
HDAC5 protected against AF remodeling via binding to MEF2 and
suppression of MEF2-related fetal gene program. Consequently, com-
pounds inhibiting the release of HDAC5 from MEF2 might have a
therapeutic potential for treatment of AF. One such compound,
MC1568 [31], protected against tachypacing-induced contractile dys-
function in both HL-1 and Drosophila models for AF. Also, inhibitors of
upstream kinases, which phosphorylate HDAC5 and thus initiate de-
repression of MEF2, would also be of interest. An example is inhibition
of CaMK or PKC, since these represent two main kinases involved in
HDAC5 phosphorylation and nuclear export in cardiomyocytes [44].
Indeed, CaMK inhibitors have been reported to prevent AF [39]. Fur-
thermore, the PKC inhibitor Go6983 has been reported to block HDAC5
Fig. 8. HDAC3 inhibitor protects against tachypa-
cing-induced contractile dysfunction in HL-1 cardi-
omyocytes and Drosophila. A, B) Representative CaT
traces and quantiﬁed data showing speciﬁc HDAC3
inhibitor RGFP966 (5 μM) protects against tachypa-
cing-induced CaT loss in HL-1 cardiomyocytes.
Cardiomyocytes are treated with either DMSO (CTL)
or 5 μM RGFP966 before tachypacing. **P < 0.01
vs CTL NP, ###P < 0.001 vs CTL TP. N=10 car-
diomyocytes per group, two independent experi-
ments. C-E) Representative heart wall traces and
quantiﬁed data showing speciﬁc HDAC3 inhibitor
RGFP966 (50 μM) protects against tachypacing-in-
duced heart rate reduction and increased ar-
rhythmicity in Drosophila prepupa. *P < 0.05 vs
CTL NP, **P < 0.01 vs CTL NP, #P < 0.05 vs CTL
TP. N=11 Drosophila per group.
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nuclear export and also α-tubulin deacetylation after nerve injury
[28,32]. We found Go6983 to prevent tachypacing-induced remodeling
in HL-1 cardiomyocytes and Drosophila models for AF. Thus, our study
suggests HDAC5 repression of MEF2 responsive genes to be involved in
AF. Therefore, HDAC5 nuclear boosters, which prevent stress-induced
HDAC5 release from MEF2, such as MC1568 and PKC inhibitor Go6983,
might represent novel therapeutic approaches to attenuate AF pro-
gression.
4.4. Limitations of the study
We describe the role of class I and IIa HDACs on cardiomyocyte
dysfunction in AF by utilizing tachypaced HL-1 cardiomyocyte (mouse
atrial tumor cells) and Drosophila model systems for AF related re-
modeling, because both systems have merit to identify potential sig-
naling pathways involved in AF remodeling. As a result, ﬁndings have
been conﬁrmed repeatedly in the tachypaced dog model for AF and
clinical AF [17,46,47]. Nevertheless, caution must be taken in extra-
polating ﬁndings from the model systems to clinical AF. In addition, the
current study provides evidence for a role of HDAC3 and HDAC5 ac-
tivation in AF. Future studies should elucidate the upstream pathways
involved in the activation of HDAC3 or HDAC5.
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